Publications by authors named "Neil T Thompson"

Claim this Profile
R
Repurposing statins and phenothiazines to treat chemoresistant neuroblastoma.
Katarzyna Radke, Kristina Aaltonen, Erick A Muciño-Olmos, Javanshir Esfandyari, Aleksandra Adamska, Neil T Thompson

EMBO Mol Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity.
Timothy A Yap, Mike I Walton, Kyla M Grimshaw, Robert H Te Poele, Paul D Eve, Neil T Thompson

Clin Cancer Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computational drug discovery approaches identify mebendazole as a candidate treatment for autosomal dominant polycystic kidney disease.
Philip W Brownjohn, Azedine Zoufir, Daniel J O'Donovan, Saatviga Sudhahar, Alexander Syme, Neil T Thompson

Front Pharmacol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel combination treatment for fragile X syndrome predicted using computational methods.
Wayne Chadwick, Ivan Angulo-Herrera, Patricia Cogram, Robert J M Deacon, Daniel J Mason, Neil T Thompson

Brain Commun· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK.
Joanne M Munck, Valerio Berdini, Luke Bevan, Jessica L Brothwood, Juan Castro, Neil T Thompson

Mol Cancer Ther· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein-Protein Interaction.
Gianni Chessari, Ian R Hardcastle, Jong Sook Ahn, Burcu Anil, Elizabeth Anscombe, Neil T Thompson

J Med Chem· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660).
Christopher N Johnson, Jong Sook Ahn, Ildiko M Buck, Elisabetta Chiarparin, James E H Day, Neil T Thompson

J Med Chem· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth.
George A Ward, Edward J Lewis, Jong Sook Ahn, Christopher N Johnson, John F Lyons, Neil T Thompson

Mol Cancer Ther· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2.
Tom D Heightman, Valerio Berdini, Hannah Braithwaite, Ildiko M Buck, Megan Cassidy, Neil T Thompson

J Med Chem· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.
Timothy P S Perera, Eleonora Jovcheva, Laurence Mevellec, Jorge Vialard, Desiree De Lange, Neil T Thompson

Mol Cancer Ther· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib.
Aurelie Courtin, Tomoko Smyth, Keisha Hearn, Harpreet K Saini, Neil T Thompson

Br J Cancer· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models.
Tomoko Smyth, Kim H T Paraiso, Keisha Hearn, Ana M Rodriguez-Lopez, Joanne M Munck, Neil T Thompson

Mol Cancer Ther· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.
Tomoko Smyth, Thomas Van Looy, Jayne E Curry, Ana M Rodriguez-Lopez, Agnieszka Wozniak, Neil T Thompson

Mol Cancer Ther· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.
Timothy A Yap, Mike I Walton, Kyla M Grimshaw, Robert H Te Poele, Paul D Eve, Neil T Thompson

Clin Cancer Res· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer.
Brent Graham, Jayne Curry, Tomoko Smyth, Lynsey Fazal, Ruth Feltell, Neil T Thompson

Cancer Sci· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer models.
Matthew Squires, George Ward, Gordan Saxty, Valerio Berdini, Anne Cleasby, Neil T Thompson

Mol Cancer Ther· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.
Timothy A Yap, Mike I Walton, Lisa-Jane K Hunter, Melanie Valenti, Alexis de Haven Brandon, Neil T Thompson

Mol Cancer Ther· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells.
Ruriko Tanaka, Matthew S Squires, Shinya Kimura, Asumi Yokota, Rina Nagao, Neil T Thompson

Blood· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.
Mark A Dawson, Jayne E Curry, Kelly Barber, Philip A Beer, Brent Graham, Neil T Thompson

Br J Haematol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth.
Kyla M Grimshaw, Lisa-Jane K Hunter, Timothy A Yap, Simon P Heaton, Mike I Walton, Neil T Thompson

Mol Cancer Ther· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples.
Matthew S Squires, Laurence Cooke, Victoria Lock, Wenqing Qi, E Jonathan Lewis, Neil T Thompson

Mol Cancer Ther· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.
Matthew S Squires, Ruth E Feltell, Nicola G Wallis, E Jonathan Lewis, Donna-Michelle Smith, Neil T Thompson

Mol Cancer Ther· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis